- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07637695
Silicone Barrier Spray Versus Zinc Oxide Ointment for Incontinence-Associated Dermatitis
Effectiveness of Structured Skin Care Using Silicone Barrier Spray Compared With Zinc Oxide Ointment for Incontinence-Associated Dermatitis in Long-Term Care Residents: A Randomized Controlled Trial
Incontinence-associated dermatitis (IAD) is a common skin condition among long-term care residents and is caused by prolonged exposure to urine or feces. IAD can lead to skin irritation, discomfort, impaired skin integrity, and an increased risk of secondary complications. Structured skin care, including cleansing and barrier protection, is recommended for the prevention and management of IAD.
This randomized controlled trial evaluated the effectiveness of a silicone barrier spray compared with zinc oxide ointment as part of a structured skin care program for residents with mild IAD in a long-term care facility. Participants were randomly assigned to receive either silicone barrier spray or zinc oxide ointment following routine skin cleansing. Clinical severity of IAD and skin barrier function were assessed at baseline, Day 7, and Day 14 using standardized clinical and biophysical measurements, including IAD severity score, skin hydration, transepidermal water loss, skin pH, and skin temperature. The study aimed to determine whether silicone barrier spray provides comparable or improved outcomes compared with conventional zinc oxide ointment in the management of mild IAD.
연구 개요
상태
상세 설명
Incontinence-associated dermatitis (IAD) is a common form of moisture-associated skin damage resulting from prolonged exposure of the skin to urine and/or feces. The condition is particularly prevalent among residents of long-term care facilities because of advanced age, reduced mobility, cognitive impairment, chronic illness, and urinary or fecal incontinence. IAD is associated with erythema, discomfort, pain, impaired skin barrier function, and an increased risk of secondary complications, including pressure injuries and skin infections.
Maintenance of skin barrier integrity is a fundamental component of IAD prevention and treatment. Current international guidelines recommend structured skin care programs consisting of routine cleansing, moisturization, and barrier protection. Zinc oxide-based ointments are among the most commonly used barrier products because they provide effective protection against moisture and irritants. However, zinc oxide formulations may be difficult to apply and remove, can leave residue on the skin, and may increase friction during repeated cleansing procedures.
Silicone-based barrier films represent an alternative approach to skin protection. These products form a transparent, breathable, water-resistant layer on the skin surface and may reduce friction while preserving epidermal barrier function. Sprayable silicone barrier formulations may provide additional practical advantages, including rapid application, uniform coverage, reduced physical contact with damaged skin, and improved ease of use for caregivers. Such characteristics may be particularly valuable in long-term care settings where frequent skin care interventions are required.
Despite increasing clinical use of silicone-based barrier products, direct randomized comparisons between sprayable silicone barrier films and traditional zinc oxide ointments remain limited. Furthermore, objective evaluations of skin barrier recovery using biophysical measurements have not been extensively investigated in long-term care populations with IAD.
The purpose of this study was to compare the effectiveness of a silicone barrier spray and zinc oxide ointment when incorporated into a structured skin care program for long-term care residents with mild incontinence-associated dermatitis. In addition to evaluating clinical improvement, the study investigated changes in skin barrier function using objective biophysical assessments. The findings of this study are intended to provide evidence to support clinical decision-making regarding barrier protection strategies and to improve skin care practices for vulnerable older adults residing in long-term care facilities.
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Taoyuan City
-
Longtan, Taoyuan City, 대만, 325
- Taoyuan Armed Forces General Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 어린이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
설명
Inclusion Criteria:
- Resident of a long-term care facility.
- Diagnosis of mild incontinence-associated dermatitis (IAD), classified as GLOBIAD Category 1.
- Ability to provide informed consent personally or through a legally authorized representative.
- Willingness to participate in the study and comply with study procedures.
Exclusion Criteria:
- Incontinence-associated dermatitis (IAD) classified as GLOBIAD Category 2.
- Presence of skin erosion, skin loss, open wounds, or active skin infection in the assessment area.
- Known allergy or hypersensitivity to silicone-based barrier products or zinc oxide preparations.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Silicone Barrier Spray
Participants received a silicone-based barrier spray after structured skin cleansing and moisturizing care throughout the 14-day study period.
|
A silicone-based skin barrier spray (Brava® Skin Barrier Spray, Coloplast A/S, Denmark) was applied to the perineal skin after each cleansing episode as part of a structured skin care regimen.
The spray forms a transparent, breathable, water-resistant protective film designed to reduce moisture-related skin damage and friction while maintaining skin barrier integrity.
Participants received the intervention throughout the 14-day study period following routine cleansing and moisturizing care.
|
|
활성 비교기: Zinc Oxide Ointment
Participants received zinc oxide ointment after structured skin cleansing and moisturizing care throughout the 14-day study period.
|
A traditional zinc oxide-based barrier ointment applied to the perineal skin after routine cleansing and moisturizing care.
The ointment forms a protective barrier that helps reduce skin exposure to moisture, irritants, and friction associated with urinary and fecal incontinence.
The intervention was administered as part of a structured skin care protocol throughout the 14-day study period.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in Incontinence-Associated Dermatitis Severity Score
기간: Baseline (Day 1), Day 7, and Day 14
|
Clinical severity of incontinence-associated dermatitis assessed using the modified Ghent Global Incontinence-Associated Dermatitis Monitoring Tool (GLOBIAD-M).
Scores ranged from 0 (normal skin) to 2 (more severe dermatitis), with lower scores indicating improvement in skin condition.
|
Baseline (Day 1), Day 7, and Day 14
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Skin Hydration
기간: Baseline (Day 1), Day 7, and Day 14
|
Skin hydration measured using stratum corneum capacitance at affected skin sites.
|
Baseline (Day 1), Day 7, and Day 14
|
|
Transepidermal Water Loss (TEWL)
기간: Baseline (Day 1), Day 7, and Day 14
|
Skin barrier function assessed by measuring transepidermal water loss (g/m²/h) using a closed-chamber evaporimeter.
|
Baseline (Day 1), Day 7, and Day 14
|
|
Skin pH
기간: Baseline (Day 1), Day 7, and Day 14
|
Skin surface pH measured at affected skin sites using a flat-surface electrode device.
|
Baseline (Day 1), Day 7, and Day 14
|
|
Skin Temperature
기간: Baseline (Day 1), Day 7, and Day 14
|
Skin temperature measured at affected skin sites using a skin assessment device.
|
Baseline (Day 1), Day 7, and Day 14
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Po Jen Hsiao, MD, PhD, Taoyuan Armed Forces General Hospital
- 연구 의자: Hsieh Chih Tsai, PhD, National Taiwan University of Science and Technology
- 연구 책임자: Po Chung Chen, MD, MS, Taoyuan Armed Forces General Hospital
간행물 및 유용한 링크
일반 간행물
- Bernatchez SF, Mengistu GE, Ekholm BP, Sanghi S, Theiss SD. Reducing Friction on Skin at Risk: The Use of 3M Cavilon No Sting Barrier Film. Adv Wound Care (New Rochelle). 2015 Dec 1;4(12):705-710. doi: 10.1089/wound.2015.0628.
- Holroyd S, Graham K. Prevention and management of incontinence-associated dermatitis using a barrier cream. Br J Community Nurs. 2014 Dec;Suppl Wound Care:S32-8. doi: 10.12968/bjcn.2014.19.Sup6.S32.
- McNichol LL, Ayello EA, Phearman LA, Pezzella PA, Culver EA. Incontinence-Associated Dermatitis: State of the Science and Knowledge Translation. Adv Skin Wound Care. 2018 Nov;31(11):502-513. doi: 10.1097/01.ASW.0000546234.12260.61.
- Van den Bussche K, Verhaeghe S, Van Hecke A, Beeckman D. The Ghent Global IAD Monitoring Tool (GLOBIAD-M) to monitor the healing of incontinence-associated dermatitis (IAD): Design and reliability study. Int Wound J. 2018 Aug;15(4):555-564. doi: 10.1111/iwj.12898. Epub 2018 May 24.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- TYAFGH-D-112032
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .